3 results
Approved WMOWill not start
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
Approved WMOCompleted
Primary objective is the delta change in whole body insulin sensitivity upon Na-PB vs. placebo treatment. Secondary objectives are muscle mitochondrial oxidative capacity, muscle and liver fat content and energy metabolism.
Approved WMORecruiting
Medtronic, Inc. is sponsoring the SMART Trial, a prospective, multi-center, international, randomized controlled, post-market trial. The purpose of this trial is to generate clinical evidence on valve safety and performance of SE versus BE TAVR in…